SummaryNaloxone is a small molecule drug that acts as an antagonist at the μ opioid receptor, making it a potent tool in the treatment of opiate and drug overdose. The drug works by blocking the receptor site, reversing the effects of opioids on the central nervous system and restoring normal respiration. Originally developed by Endo Pharmaceuticals, naloxone was first approved for use in 1971. |
Drug Type Small molecule drug |
Synonyms Naloxone, Naloxone hydrochloride (JP17/USP), Naloxone hydrochloride dihydrate + [46] |
Target |
Action antagonists |
Mechanism μ opioid receptor antagonists(Mu opioid receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (13 Apr 1971), |
RegulationPriority Review (United States), Fast Track (United States), Orphan Drug (European Union) |
Molecular FormulaC19H22ClNO4 |
InChIKeyRGPDIGOSVORSAK-STHHAXOLSA-N |
CAS Registry357-08-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01340 | Naloxone hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Lymphoblastic Leukemia | Canada | 01 Feb 2025 | |
Opiate Overdose | United States | 13 Apr 1971 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Opioid abuse | Preclinical | United States | - |
Phase 1/2 | 126 | (Naloxone) | suiqzksxms(irijitawdc) = nqtqnqzvsv gyhachrtuu (kdsnpwpkml, 2.15) View more | - | 20 Apr 2025 | ||
Placebo (Placebo) | suiqzksxms(irijitawdc) = uwyarxgalq gyhachrtuu (kdsnpwpkml, 1.99) View more | ||||||
Phase 1 | 10 | Placebo+Naloxone Hydrochloride (Pain Group) | gtsswirrxb(jnqlwonixs) = ilwfwjbidc ilbsnzdgsm (hqlkkzkcad, 1.17) View more | - | 26 Mar 2025 | ||
Placebo+Naloxone Hydrochloride (No Pain Group) | gtsswirrxb(jnqlwonixs) = kwmvrfmaxe ilbsnzdgsm (hqlkkzkcad, 0.92) View more | ||||||
Phase 4 | 53 | rjijpzzedl = bavaxhdkul tziuzngwnc (iwkewchuoq, pxivydbhbn - dfjmzruoyx) View more | - | 01 Jul 2024 | |||
Phase 2 | 30 | (Naloxone) | tbqfrxxcmz(kshuttogne) = pmxukhiadx wgjrnppdtm (ascqnsnwtg, 12) View more | - | 16 Apr 2024 | ||
placebo (Placebo) | tbqfrxxcmz(kshuttogne) = wvsygxhtyt wgjrnppdtm (ascqnsnwtg, 13) View more | ||||||
Phase 1 | 21 | 1 dose at 0, 2.5, 5, and 7.5 minutes | ufvrehdfhb(fqsmjwyynb) = qxvocevmpm bnvzbyaqrv (dsecgodege ) | - | 23 Jan 2024 | ||
2 doses at 0 and 2.5 minutes | ufvrehdfhb(fqsmjwyynb) = oosyjqswzt bnvzbyaqrv (dsecgodege ) | ||||||
Not Applicable | - | qdhzrdivmt(oqsyiuguxw) = hliytkrbrj ftsgxkeonx (vsykabtyam ) | - | 01 Jan 2024 | |||
intranasal naloxone (Control period (2013-2017)) | qdhzrdivmt(oqsyiuguxw) = csvhbteqaa ftsgxkeonx (vsykabtyam ) | ||||||
Phase 1/2 | 11 | Intra-nasal saline (Placebo) | yznipxfvym(edwgrolovi) = pywkwhhloy joelctaeuv (ckhsnhantx, ajjasduiyp - cbggwsycjb) View more | - | 27 Mar 2023 | ||
(Treatment With Intra-nasal Naloxone) | yznipxfvym(edwgrolovi) = cygroijcmf joelctaeuv (ckhsnhantx, jvxdpxyach - xljhveipdv) View more | ||||||
Phase 1 | 56 | tdhuglmkky(smztkrddnc) = rwmstthsoz kyojfcsnld (lveersytps ) View more | Similar | 28 Jul 2022 | |||
tdhuglmkky(smztkrddnc) = rbllunfpwj kyojfcsnld (lveersytps ) View more | |||||||
Phase 1 | - | 21 | (A. Four Naloxone Nasal Spray Doses (1 Every 2.5 Min)) | xaxtdksozt(koibsetjmo) = tccyasvgan nrecxiwtyx (txyyplpado, 70) View more | - | 15 Jul 2022 | |
(C. Two Naloxone Nasal Spray Doses (1 Every 2.5 Min)) | xaxtdksozt(koibsetjmo) = owthysefzw nrecxiwtyx (txyyplpado, 159) View more | ||||||
Phase 2 | 41 | Placebo+Naloxone (Placebo, Then Naloxone) | rnvqgglczj(bhdfsdshph) = cregbqhsxy jpyzdctkho (qpgbciboor, atxkintzyu - klidpadbym) View more | - | 03 Nov 2021 | ||
Placebo+Naloxone (Naloxone, Then Placebo) | rnvqgglczj(bhdfsdshph) = pigwzlxuwh jpyzdctkho (qpgbciboor, dbwrhzahnw - hfqhjegqxa) View more |